Most of onset causes are said to be human papillomavirus (HPV), and vaccine is developed only by this human papillomavirus, and the vaccinotherapy of the uterine cervix cancer approves vaccine of the neck cancer prevention that FDA (it is American Food and Drug Administration) calls a girder sill (vaccine of the uterine cervix cancer which American pharmaceutical company Merck & Co. developed).
As for the girder sill being related to uterine cervix cancer with the 4 values vaccine acting on 6 type, 11 type, 16 type and 18 type of the virus model that it is especially said to that relations are deep for the neck cancer onset in human papillomavirus having a model more than 100 kinds directly, as for 6 type, 11 type, it is with the main cause of senkei konjiroma (a wart) to develop to the sexual organs with 16 type, 18 type.
The girder sill prevents cancer 100% before the result uterine cervix cancer which you took in to result 16 type, non-infection woman (16 years old - 26 years old) of 18 type whom FDA examined three times, and there is it when you prevented an uterocervical lesion of result 95.2% that 6 type, 11 type, 16 type, both 18 types took in to a woman (16 years old - 26 years old) of non-infection three times, and it may be said that it is the vaccine which is effective for the prevention of the provision neck cancer.
Because you develop vaccine to call "server Rick" and approve it and applied for English GlaxoSmithKline Corporation (GSK), it seems that perhaps European and American, it is approved as the second uterine cervix cancer vaccine.
kadashiru which is effective for the onset prevention of this uterine cervix cancer was it during clinical experiment, but thinks that the Japanese authorization examination that enormous time hangs for the authorization is not approved without yet going.
Furthermore, you think that the approval application may not be given by GSK company when you reach "server Rick".
